SHANGHAI – Cayman-registered Hutchison China Meditech Ltd. has updated its SEC F-1 filing for a third time since it announced its intention to go public in the U.S. under the stock ticker HCM. There is a wealth of financial and scientific data to pore over, as one of China’s first biotechs Hutchison has a multipronged business that includes 19 active studies for seven clinical-stage therapies for oncology and immunological diseases, licensing deals with big pharma and diversified commercial operations for prescription and OTC drugs. But the one item still missing from the prospectus is a share price.